WOCKPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.7
| Stock Code | WOCKPHARMA | Market Cap | 22,677 Cr. | Current Price | 1,396 ₹ | High / Low | 1,870 ₹ |
| Stock P/E | 113 | Book Value | 178 ₹ | Dividend Yield | 0.00 % | ROCE | 4.40 % |
| ROE | -0.53 % | Face Value | 5.00 ₹ | DMA 50 | 1,343 ₹ | DMA 200 | 1,367 ₹ |
| Chg in FII Hold | 0.09 % | Chg in DII Hold | 0.41 % | PAT Qtr | 38.0 Cr. | PAT Prev Qtr | 54.0 Cr. |
| RSI | 56.4 | MACD | 35.4 | Volume | 5,24,780 | Avg Vol 1Wk | 5,04,674 |
| Low price | 1,087 ₹ | High price | 1,870 ₹ | PEG Ratio | 4.67 | Debt to equity | 0.76 |
| 52w Index | 39.4 % | Qtr Profit Var | 273 % | EPS | 11.8 ₹ | Industry PE | 30.1 |
📈 Optimal Buy Price: 1,385 ₹ – 1,400 ₹
🎯 Profit Exit Levels: 1,420 ₹ – 1,450 ₹
🛡️ Stop-Loss: 1,370 ₹
⏳ Intraday Exit Guidance:
If already holding, consider exiting if RSI dips below 54 with rising volume or if price fails to sustain above 1,396 ₹. Momentum exits are near 1,420–1,450 ₹; book profits if volume fades or MACD weakens intraday.
---
Positive
✔️ EPS at 11.8 ₹ provides valuation support
✔️ Price above DMA 50 (1,343 ₹) and DMA 200 (1,367 ₹), showing short-term strength
✔️ MACD positive (35.4), indicating bullish momentum
✔️ Volume slightly above weekly average, supporting intraday participation
✔️ DII holdings increased (+0.41%), showing domestic institutional support
Limitation
⚠️ High P/E (113) vs industry average (30.1) indicates extreme overvaluation
⚠️ ROCE (4.40%) and ROE (-0.53%) highlight weak efficiency
⚠️ Debt-to-equity ratio at 0.76 is relatively high
⚠️ PAT declined (38 Cr. vs 54 Cr.), showing earnings pressure
⚠️ PEG ratio 4.67 suggests expensive growth
Company Negative News
❌ Quarterly profit contraction (-30% approx.)
❌ Weak efficiency metrics (ROCE/ROE)
❌ High leverage compared to peers
Company Positive News
✅ EPS remains consistent despite profit decline
✅ DII holdings increased, showing domestic support
✅ RSI at 56.4 indicates neutral-to-positive momentum
Industry
🏭 Industry PE at 30.1, moderately valued compared to company’s premium
📊 Pharma sector remains resilient with steady demand
📈 Peers trade at lower valuations, offering alternatives
Conclusion
WOCKPHARMA is a speculative intraday candidate with short-term bullish technicals but weak fundamentals. High valuation, declining profits, and leverage risks limit upside. Best suited for cautious intraday trades with strict stop-losses and profit booking near resistance levels.
Would you like me to extend this into a sector overlay vs peers (Sun Pharma, Dr. Reddy’s, Cipla) so you can benchmark WOCKPHARMA’s intraday setup against stronger pharma players?